Vareniclin - Erhöhtes kardiovaskuläres risiko bei der raucherentwöhnung?

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • M. Dewenter - , University of Göttingen (Author)
  • A. El-Armouche - , University of Göttingen (Author)

Abstract

Smoking is one of the most important cardiovascular risk factors. Varenicline, a partial agonist of the α 4β 2 nicotinic acetylcholine receptor, has been demonstrated to be the most efficacious medication for smoking cessation. However, treatment with varenicline has sometimes been associated with severe cardiovascular side effects. This article discusses the current data with respect to the cardiovascular safety of varenicline therapy.

Translated title of the contribution
Varenicline - Increased cardiovascular risk in smoking cessation?

Details

Original languageGerman
Pages (from-to)240-243
Number of pages4
JournalDer Kardiologe : die Fortbildungszeitschrift der Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung
Volume6
Issue number3
Publication statusPublished - Jun 2012
Peer-reviewedYes
Externally publishedYes

External IDs

ORCID /0000-0003-2514-9429/work/151982637

Keywords

ASJC Scopus subject areas

Keywords

  • Cardiovascular risk, Nicotine dependence, Nicotine receptor partial agonist, Smoking cessation, Varenicline